Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt N/A
JNJ's Cash-to-Debt is ranked higher than
85% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. JNJ: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
JNJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62  Med: 1.63 Max: N/A
Current: N/A
Equity-to-Asset 0.52
JNJ's Equity-to-Asset is ranked lower than
65% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. JNJ: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.66
Current: 0.52
0.5
0.66
Interest Coverage 33.76
JNJ's Interest Coverage is ranked lower than
60% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. JNJ: 33.76 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 36.85 Max: 59.04
Current: 33.76
28.29
59.04
WACC vs ROIC
7.06%
31.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 29.40
JNJ's Operating Margin % is ranked higher than
92% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.38 vs. JNJ: 29.40 )
Ranked among companies with meaningful Operating Margin % only.
JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 22.36  Med: 25.78 Max: 29.4
Current: 29.4
22.36
29.4
Net Margin % 22.78
JNJ's Net Margin % is ranked higher than
90% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. JNJ: 22.78 )
Ranked among companies with meaningful Net Margin % only.
JNJ' s Net Margin % Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 23.01
Current: 22.78
14.87
23.01
ROE % 22.71
JNJ's ROE % is ranked higher than
85% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.12 vs. JNJ: 22.71 )
Ranked among companies with meaningful ROE % only.
JNJ' s ROE % Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 46.49
Current: 22.71
17.02
46.49
ROA % 11.99
JNJ's ROA % is ranked higher than
83% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. JNJ: 11.99 )
Ranked among companies with meaningful ROA % only.
JNJ' s ROA % Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 24.8
Current: 11.99
8.93
24.8
ROC (Joel Greenblatt) % 105.30
JNJ's ROC (Joel Greenblatt) % is ranked higher than
93% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.08 vs. JNJ: 105.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 248.72
Current: 105.3
65.66
248.72
3-Year Revenue Growth Rate 1.30
JNJ's 3-Year Revenue Growth Rate is ranked lower than
64% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. JNJ: 1.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 7.2 Max: 14.8
Current: 1.3
1.3
14.8
3-Year EBITDA Growth Rate 2.80
JNJ's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. JNJ: 2.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 10 Max: 16.7
Current: 2.8
-6.6
16.7
3-Year EPS without NRI Growth Rate 7.20
JNJ's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. JNJ: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 10.9 Max: 20.2
Current: 7.2
-8.6
20.2
GuruFocus has detected 4 Warning Signs with Johnson & Johnson $JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JNJ's 10-Y Financials

Financials (Next Earnings Date: 2017-04-19)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

JNJ Guru Trades in Q1 2016

Diamond Hill Capital 1,969 sh (New)
David Rolfe 5,250 sh (New)
Jim Chanos 29,730 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Yacktman Fund 3,600,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Richard Snow 3,260 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Perry 292,729 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Michael Price 25,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Jim Chanos 5,952 sh (unchged)
David Carlson 460,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
Q2 2016

JNJ Guru Trades in Q2 2016

Ray Dalio 129,700 sh (New)
Tom Russo 2,050 sh (New)
Louis Moore Bacon 3,552 sh (New)
Lee Ainslie 28,230 sh (New)
John Paulson 128,000 sh (New)
Jim Chanos 49,843 sh (+67.65%)
RS Investment Management 10,007 sh (+19.17%)
Jeremy Grantham 9,741,420 sh (+7.80%)
Diamond Hill Capital 2,110 sh (+7.16%)
Dodge & Cox 35,185 sh (+1.08%)
John Rogers 857,563 sh (+0.78%)
John Buckingham 63,881 sh (+0.38%)
Mairs and Power 2,185,819 sh (+0.03%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
John Hussman 25,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Michael Price 25,000 sh (unchged)
Richard Perry 292,729 sh (unchged)
David Rolfe 5,250 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Carlson 460,000 sh (unchged)
Chuck Royce Sold Out
John Burbank Sold Out
Jeff Auxier 105,126 sh (-0.05%)
Ken Fisher 10,845,150 sh (-0.08%)
Murray Stahl 30,622 sh (-0.49%)
Richard Snow 3,220 sh (-1.23%)
Paul Tudor Jones 15,553 sh (-2.03%)
Tweedy Browne 3,216,513 sh (-4.93%)
Donald Yacktman 6,671,349 sh (-5.78%)
PRIMECAP Management 2,830,937 sh (-6.37%)
Manning & Napier Advisors, Inc 3,297,804 sh (-6.93%)
Richard Pzena 1,103,032 sh (-6.94%)
Ruane Cunniff 12,933 sh (-7.12%)
Mario Gabelli 312,831 sh (-7.33%)
Charles Brandes 133,128 sh (-8.97%)
Pioneer Investments 3,223,857 sh (-12.28%)
Barrow, Hanley, Mewhinney & Strauss 13,210,591 sh (-13.81%)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
Robert Olstein 41,000 sh (-18.00%)
First Eagle Investment 759,790 sh (-33.52%)
Sarah Ketterer 787,234 sh (-42.30%)
Jim Simons 626,100 sh (-73.70%)
Joel Greenblatt 4,906 sh (-97.97%)
» More
Q3 2016

JNJ Guru Trades in Q3 2016

Eaton Vance Worldwide Health Sciences Fund 450,936 sh (New)
Joel Greenblatt 214,043 sh (+4262.88%)
Jim Simons 1,475,100 sh (+135.60%)
Paul Tudor Jones 28,124 sh (+80.83%)
Diamond Hill Capital 2,296 sh (+8.82%)
Pioneer Investments 3,454,669 sh (+7.16%)
John Rogers 858,549 sh (+0.11%)
Tweedy Browne Global Value 865,835 sh (unchged)
John Hussman 25,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Ken Fisher 10,845,620 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,250 sh (unchged)
Richard Perry Sold Out
Tom Russo Sold Out
Richard Snow 3,215 sh (-0.16%)
Dodge & Cox 34,985 sh (-0.57%)
T Rowe Price Equity Income Fund 3,380,000 sh (-0.59%)
Jeff Auxier 104,176 sh (-0.90%)
Mairs and Power 2,153,237 sh (-1.49%)
John Buckingham 62,429 sh (-2.27%)
Charles Brandes 126,627 sh (-4.88%)
Mario Gabelli 294,127 sh (-5.98%)
Murray Stahl 28,648 sh (-6.45%)
Barrow, Hanley, Mewhinney & Strauss 12,334,416 sh (-6.63%)
Lee Ainslie 26,320 sh (-6.77%)
Tweedy Browne 2,978,783 sh (-7.39%)
Yacktman Focused Fund 1,800,000 sh (-7.69%)
Donald Yacktman 6,143,753 sh (-7.91%)
Manning & Napier Advisors, Inc 3,028,532 sh (-8.17%)
Richard Pzena 1,002,314 sh (-9.13%)
Sarah Ketterer 705,335 sh (-10.40%)
PRIMECAP Management 2,519,397 sh (-11.00%)
Yacktman Fund 3,200,000 sh (-11.11%)
Louis Moore Bacon 2,875 sh (-19.06%)
Michael Price 20,000 sh (-20.00%)
Jeremy Grantham 7,282,964 sh (-25.24%)
Robert Olstein 30,000 sh (-26.83%)
Jim Chanos 35,387 sh (-29.00%)
Ruane Cunniff 5,713 sh (-55.83%)
Ray Dalio 44,400 sh (-65.77%)
John Paulson 35,000 sh (-72.66%)
First Eagle Investment 28,177 sh (-96.29%)
» More
Q4 2016

JNJ Guru Trades in Q4 2016

Steven Cohen 245,700 sh (New)
Jim Simons 3,423,100 sh (+132.06%)
Joel Greenblatt 475,722 sh (+122.26%)
Prem Watsa 151,250 sh (+82.56%)
Pioneer Investments 4,830,327 sh (+39.82%)
Sarah Ketterer 769,679 sh (+9.12%)
Lee Ainslie 28,530 sh (+8.40%)
Charles Brandes 131,352 sh (+3.73%)
John Rogers 870,359 sh (+1.38%)
Diamond Hill Capital 2,327 sh (+1.35%)
Ken Fisher 10,957,134 sh (+1.03%)
John Buckingham 62,716 sh (+0.46%)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Yacktman Focused Fund 1,800,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Richard Snow 3,215 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Michael Price 20,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
David Rolfe 5,250 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 450,936 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Jim Chanos Sold Out
John Paulson Sold Out
T Rowe Price Equity Income Fund 3,370,000 sh (-0.30%)
Richard Pzena 998,964 sh (-0.33%)
Mairs and Power 2,143,539 sh (-0.45%)
First Eagle Investment 28,031 sh (-0.52%)
Donald Yacktman 6,035,969 sh (-1.75%)
Dodge & Cox 34,185 sh (-2.29%)
Manning & Napier Advisors, Inc 2,942,895 sh (-2.83%)
Robert Olstein 29,000 sh (-3.33%)
Barrow, Hanley, Mewhinney & Strauss 11,875,386 sh (-3.72%)
Murray Stahl 26,905 sh (-6.08%)
Ruane Cunniff 5,238 sh (-8.31%)
Mario Gabelli 257,586 sh (-12.42%)
PRIMECAP Management 2,171,097 sh (-13.82%)
Tweedy Browne 2,386,562 sh (-19.88%)
Jeremy Grantham 5,255,334 sh (-27.84%)
Paul Tudor Jones 5,800 sh (-79.38%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, NYSE:MRK, NYSE:NVS, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:BMY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Guru Investment Theses on Johnson & Johnson

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Top Ranked Articles about Johnson & Johnson

GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Isaly, the only manager to beat the market for 25 consecutive years, talks about pressing issues in the sector
Samuel Isaly is one of the foremost health care investors in the U.S. He founded OrbiMed Advisors, a global management firm with $13 billion in assets that invests across biotech, pharmaceuticals, medical devices, digital innovations and other areas of the industry. In January 2016, Barron’s Magazine recognized him as the only U.S. mutual fund manager to beat the S&P 500 for 25 consecutive years ending Nov. 30, 2015. Read more...
Why Shareholders Care About Dividends A 3% yield may not sound exciting, but there are many good reasons why investors care about dividends
(Published Jan. 27 by The Financial Canadian) Read more...
The Difference Between the Ex-Dividend Date, Record Date and Pay Date Clearing up confusion and common misconceptions about the dividend payment process
(Published Jan. 23 by The Financial Canadian) Read more...
Health Care Companies Showing Good Defensive Potential Deep analysis of historical financial trends for health care companies
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson (NYSE:JNJ), Biogen Inc. (NASDAQ:BIIB) and VCA Inc. (NASDAQ:WOOF), generally had strong financial strength and gross margins. Read more...
Donald Yacktman Reduces Multiple Positions in 3rd Quarter An overview of the guru's largest sales of the quarter
Donald Yacktman (Trades, Portfolio) founded Yacktman Asset Management in 1992. His son, Stephen Yacktman, now primarily runs the firm. During the third quarter, the guru reduced his position in the following stocks: Read more...
Tweedy Browne Sells Halliburton, Johnson & Johnson An overview of the fund's largest trades in the 3rd quarter
Tweedy Browne is an investment partnership owned by its four managing directors, William H. Browne, John D. Spears, Thomas H. Shrager and Robert Q. Wyckoff Jr. During the third quarter the guru firm's largest sales were: Read more...
Samuel Isaly Makes 9 New Buys in 3rd Quarter 5 acquisitions have impacts greater than 2% on portfolio
Samuel Isaly (Trades, Portfolio) of Eaton Vance Worldwide Health Sciences Fund acquired nine new holdings in the third quarter ended Aug. 31. Five of the holdings had impacts greater than 2% on the portfolio. Read more...
What Rate of Return Will an Investment in Johnson & Johnson Deliver? Part 2 Further analysis of J&J's rate of return
Introduction Read more...
Valuation Is a Measurement of Soundness and Not the Primary Total Return Producer: Part 1 Analysis of Consolidated Edison, Johnson & Johnson and Cisco
Introduction Read more...
Ariel Funds Comments on Johnson & Johnson Guru stock highlight
Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward. Read more...

Ratios

vs
industry
vs
history
PE Ratio 20.82
JNJ's PE Ratio is ranked higher than
66% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.06 vs. JNJ: 20.82 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 17.68 Max: 24
Current: 20.82
10.5
24
Forward PE Ratio 17.30
JNJ's Forward PE Ratio is ranked lower than
55% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.82 vs. JNJ: 17.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.82
JNJ's PE Ratio without NRI is ranked higher than
67% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.19 vs. JNJ: 20.82 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 17.68 Max: 24
Current: 20.82
10.5
24
Price-to-Owner-Earnings 27.94
JNJ's Price-to-Owner-Earnings is ranked higher than
57% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.27 vs. JNJ: 27.94 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.19  Med: 17.56 Max: 28.01
Current: 27.94
10.19
28.01
PB Ratio 4.59
JNJ's PB Ratio is ranked lower than
71% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. JNJ: 4.59 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.7 Max: 4.99
Current: 4.59
2.68
4.99
PS Ratio 4.75
JNJ's PS Ratio is ranked lower than
69% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. JNJ: 4.75 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.95
Current: 4.75
2.17
4.95
Price-to-Free-Cash-Flow 34.20
JNJ's Price-to-Free-Cash-Flow is ranked lower than
67% of the 185 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.92 vs. JNJ: 34.20 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.28  Med: 16.56 Max: 34.31
Current: 34.2
10.28
34.31
Price-to-Operating-Cash-Flow 28.20
JNJ's Price-to-Operating-Cash-Flow is ranked lower than
73% of the 233 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.34 vs. JNJ: 28.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.98  Med: 13.23 Max: 28.27
Current: 28.2
8.98
28.27
EV-to-EBIT 16.12
JNJ's EV-to-EBIT is ranked higher than
61% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.61 vs. JNJ: 16.12 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.9 Max: 18.2
Current: 16.12
7.8
18.2
EV-to-EBITDA 14.27
JNJ's EV-to-EBITDA is ranked higher than
57% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.32 vs. JNJ: 14.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.9 Max: 14.8
Current: 14.27
6.7
14.8
PEG Ratio 2.99
JNJ's PEG Ratio is ranked lower than
66% of the 266 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. JNJ: 2.99 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.65  Med: 2.85 Max: 14.89
Current: 2.99
1.65
14.89
Shiller PE Ratio 24.67
JNJ's Shiller PE Ratio is ranked higher than
78% of the 157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.81 vs. JNJ: 24.67 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.52  Med: 20.84 Max: 26.8
Current: 24.67
15.52
26.8
Days Inventory 139.50
JNJ's Days Inventory is ranked lower than
62% of the 567 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.74 vs. JNJ: 139.50 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 67.77  Med: 103.67 Max: 139.5
Current: 139.5
67.77
139.5
Days Sales Outstanding 59.90
JNJ's Days Sales Outstanding is ranked higher than
66% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. JNJ: 59.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 56.88 Max: 61.4
Current: 59.9
53.94
61.4
Days Payable 100.50
JNJ's Days Payable is ranked higher than
69% of the 471 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. JNJ: 100.50 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 109.64 Max: 147.94
Current: 100.5
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.62
JNJ's Dividend Yield % is ranked higher than
73% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. JNJ: 2.62 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.05  Med: 2.84 Max: 3.84
Current: 2.62
2.05
3.84
Dividend Payout Ratio 0.54
JNJ's Dividend Payout Ratio is ranked lower than
69% of the 378 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. JNJ: 0.54 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.51 Max: 0.65
Current: 0.54
0.39
0.65
3-Year Dividend Growth Rate 6.70
JNJ's 3-Year Dividend Growth Rate is ranked lower than
55% of the 270 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. JNJ: 6.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.7  Med: 12.1 Max: 17.1
Current: 6.7
6.7
17.1
Forward Dividend Yield % 2.61
JNJ's Forward Dividend Yield % is ranked higher than
72% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.61 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.67
JNJ's 5-Year Yield-on-Cost % is ranked higher than
76% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. JNJ: 3.67 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.88  Med: 3.98 Max: 5.39
Current: 3.67
2.88
5.39
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.1 Max: 2.3
Current: 1.2
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 15.19
JNJ's Price-to-Tangible-Book is ranked lower than
92% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. JNJ: 15.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
JNJ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.74  Med: 11.36 Max: 17.97
Current: 15.19
6.74
17.97
Price-to-Intrinsic-Value-Projected-FCF 2.62
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
50% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.61 vs. JNJ: 2.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.49 Max: 3.6
Current: 2.62
0.98
3.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.95
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
70% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. JNJ: 1.95 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.47
JNJ's Price-to-Median-PS-Value is ranked lower than
66% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.22 vs. JNJ: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.83  Med: 1.18 Max: 1.76
Current: 1.47
0.83
1.76
Price-to-Peter-Lynch-Fair-Value 2.15
JNJ's Price-to-Peter-Lynch-Fair-Value is ranked lower than
66% of the 163 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. JNJ: 2.15 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JNJ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.27  Med: 1.89 Max: 3.85
Current: 2.15
1.27
3.85
Price-to-Graham-Number 3.82
JNJ's Price-to-Graham-Number is ranked lower than
99.99% of the 331 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. JNJ: 3.82 )
Ranked among companies with meaningful Price-to-Graham-Number only.
JNJ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0  Med: 3.26 Max: 5.43
Current: 3.82
0
5.43
Earnings Yield (Greenblatt) % 6.20
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 611 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. JNJ: 6.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.5  Med: 7.7 Max: 12.9
Current: 6.2
5.5
12.9
Forward Rate of Return (Yacktman) % 13.45
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 353 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.48 vs. JNJ: 13.45 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.6  Med: 11.45 Max: 15.5
Current: 13.45
-2.6
15.5

More Statistics

Revenue (TTM) (Mil) $71,890
EPS (TTM) $ 5.88
Beta0.64
Short Percentage of Float0.57%
52-Week Range $102.97 - 126.07
Shares Outstanding (Mil)2,720.53

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 74,975 77,332 82,447
EPS ($) 7.10 7.51 7.92
EPS without NRI ($) 7.10 7.51 7.92
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.25%
Dividends per Share ($) 3.36 3.53 3.84
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
US Market Indexes Gain for the Week Feb 26 2017 
Dow Jones Leads Market Gains on Thursday Feb 23 2017 
3 Dividend Stocks for 2017 Feb 21 2017 
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017 
4 Companies Affected by Strength of the US Dollar Feb 13 2017 
4 Companies That Will Benefit From Trump’s Repatriation Tax Reform Feb 13 2017 
3 Dividend Stocks for 2017 Feb 13 2017 
GuruFocus Interview: Orbimed Guru Sam Isaly on Investing in New Era of Healthcare Feb 15 2017 
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Merck: Analyzing 2016 Performance and Outlook for 2017 Feb 04 2017 

More From Other Websites
[$$] The New Normal for Drug Makers Feb 27 2017
[$$] Johnson & Johnson Prescription Unit List Prices Rose 8.5% Last Year Feb 27 2017
The world's biggest drugmaker just pulled back the curtain on drug pricing Feb 27 2017
Drugmakers pledge restraint, but prices will still soar Feb 27 2017
Drugmakers pledge restraint, but prices will still soar Feb 27 2017
JOHNSON & JOHNSON Files SEC form 10-K, Annual Report Feb 27 2017
[$$] Johnson & Johnson Prescription Unit List Prices Rose 8.5% Last Year Feb 27 2017
J&J says kept drug price increases below 10 percent since 2012 Feb 27 2017
J&J says kept drug price increases below 10 pct since 2012 Feb 27 2017
J&J reveals 3.5% net hike in drug pricing last year Feb 27 2017
Jim Cramer Is Passing on Valeant Ahead of Earnings Feb 27 2017
Johnson & Johnson Transparency Report Shows 3.5% Increase in Drug Prices Feb 27 2017
Johnson & Johnson reveals 3.5% net hike in drug pricing l... Feb 27 2017
Johnson & Johnson lifts lid on drug pricing data, shows 3.5% net hike in 2016 Feb 27 2017
Ortho Clinical Diagnostics Awarded Top Honor for Global Excellence in Customer Service Feb 27 2017
[$$] VC Profile: OrbiMed Funds Novel Attacks on Cancer Feb 27 2017
The Zacks Analyst Blog Highlights: Wal-Mart Stores, Home Depot, E I Du Pont De Nemours, Dow Chemical... Feb 27 2017
8 Dividend Stocks Every Retiree Should Own Feb 27 2017
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss Feb 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)